• Bhawana Sharma Reproductive Toxicology Unit, Department of Zoology, University of Rajasthan, Jaipur- 302004, India
  • Priyanka Sharma Reproductive Toxicology Unit, Department of Zoology, University of Rajasthan, Jaipur- 302004, India
  • S. C. Joshi Reproductive Toxicology Unit, Department of Zoology, University of Rajasthan, Jaipur- 302004, India




Progeria, Hutchsion Gliford Syndrome, Rapid Aging, Lmna Gene, Osteolysis, Microganthia


Progeria also known Hutchinson–Gilford progeria syndrome (HGPS), is an extremely rare genetic disorder. The prevalence of HGPS is 1 in 4-8 million newborns. Progeria causes premature, rapid aging shortly after birth present within the first year of life. Recently, de novo point mutations in the Lmna gene at position 1824 of the coding sequence have been found in persons with HGPS. Lmna encodes lamin A and C, the A-type lamins, which are an important structural component of the nuclear envelope and play a role in protein processing. The most common HGPS mutation is located at codon 608 (G608G). This mutation responsible for creating a cryptic splice site within exon 11, which deletes a proteolytic cleavage site within the expressed mutant lamin A. In Progeria, gene mutation results in the deletion of a Zmpste24/FACE1 splice site in prelamin A, preventing end terminal cleavage. The result of this point mutation can be observed by the main clinical and radiological features include alopecia, thin skin hypoplasia of nails, loss of subcutaneous fat, and osteolysis. The common symptoms of HGPS is a loss of eyebrows and eyelashes which can observed in early childhood and due to receding hairline and blading can also observed. Generally, this patient has facial character include microganthia (small jaw), craniofacial disproportion, prominent eyes, scalp veins and alopecia (loss of hair), restricted joint mobility and severe premature atherosclerosis. Laboratory findings are unremarkable, with the exception of an increased urinary excretion of hyaluronic acid. There is presently no effective therapy is available for Hutchinson-Gilford progeria syndrome (HGPS) but, it is essential to monitor carefully cardiovascular and cerebrovascular disease So, Treatment usually includes low dose aspirin which helps prevent the atherothrombotic events, stroke and heart attacks by hindering platelet aggregation


Download data is not yet available.


Gilford H. On a condition of mixed premature and immature development. Med Chir Trans 1897;80:17–46.

Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamina cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293–8.

Gilford H. Ateleiosis and progeria: continuous youth and premature old age. Br Med J 1904;2:914–8.

Hutchinson J. Case of congenital absence of hair, the with atrophic condition of the skin and its appendages, in a boy whose mother had been almost wholly balk from alopeciaareata from the age of six. Lancet 1886;I:923.

Beauregard S, Gilchrest BA. Syndromes of premature aging. Dermatol Clin 1987;5:109–21.

Khalifa MM. Hutchinson-Gilford progeria syndrome: report of a Libyan family and evidence of autosomal recessive inheritance. Clin Genetics 1989;35:125–32.

DeBusk FL. The Hutchinson-Gilford progeria syndrome. J Pediatr 1972;90:697–724.

Shumaker DK, E Kuczmarski ER, Goldman RD. The nucleoskeleton: lamins and actin are major players in essential nuclear functions. Curr Opin Cell Biol 2003;15:358–66.

Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 1993;268:16321–6.

Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994;107:61–7.

Stuurman N, Heins S, Aebi U. Nuclear lamins: their structure, assembly, and interactions. J Struct Biol 1998;122:42–66.

Hennekam RCM. Hutchinson–Gilford progeria syndrome: a review of the phenotype. Am J Med Genet A 2006;140:2603-24.

Progeria Research Foundation (PRF) webpage. Available from: http://www.progeriaresearch.org/meet_the_kids.html. [Last accessed on 17 May 2014]

http://www.progeriaresearch.org/progeria_101. [Last accessed 26 Apr 2013]

Brown WT. Progeria: a human disease model of accelerated ageing. Am J Clin Nutr 1992;55:1222S–4S.

Sarkar PK, Shinton RA. Hutchinson-gilford progeria syndrome. Postgrad Med J 2001;907:312–7.

Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-gilford progeria syndrome. N Engl J Med 2008;358:592–604.

Moen C. Orthopaedic aspects of progeria. J Bone Jt Surg 1982;64:542–6.

Gamble JG. Hip disease in Hutchinson-gilford progeria syndrome. J Pediatric Orthopaedics 1984;4:585–9.

Gordon LB, Brown WT, Collins FS, Pagon RA, Bird TD, Dolan CR, et al. Hutchinson-gilford progeria syndrome. Gene Rev 2011;45:421-38.

Baker PB, Baba N, Boesel CP. Cardiovascular abnormalities in progeria. Case report and review of the literature. Arch Pathol Lab Med 1981;105:384–6.

Al-Shali KZ, Hegele RA. Laminopathies and atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:1591–5.

Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, et al. Cardiovascular pathology in Hutchinson-gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010;30:2301–9.

Prokocimer M, Davidovich M, Nissim-Rafinia M, Wiesel-Motiuk N, Bar DZ, Barkan R, et al. Nuclear lamins: key regulators of nuclear structure and activities. J Cell Mol Med 2009;13:1059–85.

Burke B, Stewart CL. Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol 2002;3:575–85.

Vergnes L, Peterfy M, Bergo MO, Young SG, Reue K. Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci USA 2004;101:10428–33.

Zaremba-Czogalla M, Dubinska-Magiera M, Rzepecki R. Laminopathies: the molecular background of the disease and the prospects for its treatment. Cell Mol Biol Lett 2011;16:114–48.

Justin Parreno, BSc, MSca b, Alyssa V Cruz. BNc accelerated aging in patients with Hutchinson-gilford progeria syndrome: clinical signs, molecular causes, treatments, and insights into the aging process. UBCMJ 2011;3:9-10.

Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. The posttranslational processing of prelamin a and disease. Annu Rev Genomics Hum Genet 2009;10:153–74.

Silvius JR, l’Heureux F. Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers. Biochemistry 1994;15:3014–22.

Boban M, Braun J, Foisner R. Lamins: structure goes cycling. Biochem Soc Trans 2010;38:301–6.

Seema N, Dharti S, Puja N, Komal S, Kavita A, Shruti C, et al. A brief review MGM’s medical college, N-6, CIDCO, Aurangabad. J Pharm Life Sci 2013;2965-2969, 2965.

Rastogi R, Chander Mohan SM. Progeria syndrome: a casereport. Indian J Orthop 2008;42:97-9.

James W, Hall III, James C. Denneny III, audiologic and otolaryngologic findings in progeria: case report. J Am Acad Audiol 1993;4:116-21.

Rajat GP, Antarmayee P, Poornima VK, Priyadarshini C, Sanat KB, Ruchi B, et al. Case report: Hutchinson-gilford progeria syndrome: a rare genetic disorder hindawi publishing corporation. Case Reports Dentistry; 2013. http://dx.doi.org/ 10.1155/2013/631378

Sowmiya R, Prabhavathy D, Jayakumar S. Progeria in siblings: a rare case report. Indian J Dermatol 2011;56:581-2.

Gordon LB, McCarten KM, Giobbie-Hurder A. Disease progression in Hutchinson-gilford progeria syndrome: impact on growth and development. Pediatrics 2007;120:824-33.

Brown WT, Zebrower M, Kieras FJ. Progeria: a genetic disease model of premature aging. In: Harrison DE. Ed. Genetic Effects on Aging II; 1990. p. 521-42.

Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, et al. Hyaluronan is not elevated in urine or serum in Hutchinson-gilford progeria syndrome. Hum Genet 2003;113:178–87.

Gray MD, Shen JC, Kamath-Loeb AS, Blank A, Sopher BL, Martin GM, et al. The Werner syndrome protein is DNA helicase. Nat Genet 1997;17:100-3.



How to Cite

Sharma, B., P. Sharma, and S. C. Joshi. “RISK FACTORS, PREVALENCE AND DIAGNOSIS OF HUTCHISON GILFORD SYNDROME WITH SPECIAL REFERENCE TO CASE REPORTS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 5, May 2017, pp. 1-5, doi:10.22159/ijpps.2017v9i5.16282.



Case Study(s)